TrialAssure Launches Anonymize 3.0 Technology for an Improved Data and Document Anonymization User Experience in Pharma and Beyond

TrialAssure, a leading pharmaceutical technology provider advancing clinical trial disclosure, data sharing, and transparency, announced that its flagship product TrialAssure ANONYMIZE® 3.0 is now available. ANONYMIZE allows users across the pharmaceutical industry the ability to perform data, document, and image anonymization and redaction using machine learning (ML), natural language processing (NLP), and artificial intelligence (AI)…

Read More

90,000 sq. ft. Expansion of Grand River Aseptic Manufacturing’s Finishing and Warehouse Center is Complete

 Grand River Aseptic Manufacturing (“GRAM”), a leading sterile injectable contract manufacturer of biologics, small molecules, and vaccines, announces the completion of its finishing and warehouse center expansion. The expansion added 90,000 sq. ft. to the existing 110,000 sq. ft., totaling 200,000 sq. ft. of sophisticated inspection, packaging, testing, and warehouse capabilities. Grand River Aseptic Manufacturing…

Read More

Cayman Chemical Introduces LipidLaunch™, Expands Portfolio of Lipid Nanoparticle Research Tools to Support Advances in RNA Therapies

ANN ARBOR, MI, FEBRUARY 22, 2024 – Cayman Chemical, a leading supplier of research tools for lipid nanoparticles (LNPs), announced today the introduction of LipidLaunch™ research-ready LNPs and reagent kits. The LipidLaunch™ product line is the latest addition to the company’s portfolio of LNP research tools and reflects the company’s legacy of providing high-quality lipids…

Read More

TrialAssure Uses Artificial Intelligence to Create Plain Language Summaries for 50,000 Studies Listed on ClinicalTrials.Gov

ORIGINAL SOURCE TrialAssure’s proprietary AI-technology can aid in making clinical trial results available more quickly to all trial participants and the public The equivalent of one million work hours completed in less than one day using AI in honor of Health Literacy Month Plain language summaries to be released over a five-week period by disease…

Read More

TrialAssure Announces AI Generative Text Partnership with Top Clinical Research Organization MMS on New Medical Writing Initiative

TrialAssure, a leading software-as-a-service (SaaS) provider advancing clinical trial disclosure, data sharing, and transparency, announced today that it is collaborating with MMS, a global clinical research organization, on a new artificial intelligence (AI) initiative aimed at developing generative text specifically for medical writing in the field of drug development. The primary focus of this collaboration…

Read More

New Day Foundation for Families Announces New Day NEXT

ROCHESTER HILLS, MICH, July 1, 2023 — New Day Foundation for Families is proud to announce the launch of New Day NEXT, a young professionals’ group of passionate and motivated friends designed to cultivate the next generation of philanthropy, along with the group’s first event – a brunch following New Day’s 5K Run on Sat.,…

Read More

Cayman and Navinci Announce Strategic Partnership, Expanding Access to Next-Generation Tools for Spatial Proteomics

ORIGINAL SOURCE Ann Arbor, MI – 07/05/2023 – Global life sciences supplier Cayman Chemical (Cayman) announced today a strategic partnership with Navinci Diagnostics (Navinci), a Swedish biotechnology company developing innovative tools for spatial proteomics. This partnership expands access to Navinci’s portfolio of proximity ligation-based solutions for spatial proteomics to US- and Canada-based researchers through Cayman’s…

Read More

New Traceable Opioid Material® Kit Expands Coverage to Other Emerging Drugs of Concern in Seized Samples and Toxicological Casework

ORIGINAL SOURCE ANN ARBOR, MI, APRIL 26, 2023—Cayman Chemical and the Centers for Disease Control and Prevention (CDC) have released a new addition to the Traceable Opioid Material® Kits (TOM Kits®) product line that expands testing laboratory capabilities beyond synthetic opioids to include additional emerging drugs of abuse that are commonly found as co-drugs in fentanyl-containing samples. The new Fentanyl…

Read More

MMS Scientific Advisory Board’s New Members Expand CRO’s Therapeutic Expertise

CANTON, Mich. (3/21/2023) – MMS Holdings, an award-winning, data-focused CRO, announced today the addition of Dr. Philip Breitfeld and Dr. Bernhardt Zeiher to its board of scientific advisors. Both industry leaders in innovative clinical trial delivery solutions, Dr. Breitfeld and Dr. Zeiher’s additions as advisors expand MMS’ therapeutic area expertise to support growth in different…

Read More